<DOC>
	<DOCNO>NCT02354768</DOCNO>
	<brief_summary>Dehydration major problem high output stoma 17 % rate readmission 30 day . Dehydratations result significant electrolyte loss : sodium , potassium renal failure . Nowadays , recommendations national international high output ileostomy treatment . Apart anti-diarrhea treatment use current practice , somatostatin analog proven efficacy literature . Theses analogs permit decrease significantly gastrointestinal secretion . Several team use analogs order decrease flow highly productive ileostomy . The aim study evaluate efficacy first line treatment lanreotide associate current anti-diarrheal treatment patient high output ileostomy ( great throughput 1.5l / 24h ) without associate dehydration</brief_summary>
	<brief_title>Evaluation Lanreotide Efficacity High Output Stoma : Multicentric Randomized Study</brief_title>
	<detailed_description />
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Loperamide</mesh_term>
	<mesh_term>Antidiarrheals</mesh_term>
	<criteria>Legal time sign agreement Subject affiliate french social protection Ileostomy achieve since 10 day minimum day 0 ( D0 : start study treatment ) Ileostomy output &gt; 1.5 liter / 24h least 24 hour day 0 accept use effective method contraception study : ( 6 month follow injection lanreotide experimental group control group : 4 day last dose chlorhydrate loperamide People able understand objective , modality risk related study give write informed consent people guardianship judicial protection simultaneous participation another biomedical research protocol involve drug topic exclusion period pregnancy breastfeed administration lanreotide related peptide surgery D0 hypersensitivity lanreotide related peptide / diosmectite / loperamide / one excipients acute hemorrhagic colitis bloody diarrhea / high fever Clostridium Difficile Infection inclusion uncontrolled diabetis define HbA1c &gt; 7 % D0</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>